Vimal Kavuru - 17 Sep 2026 Form 4 Insider Report for Grace Therapeutics, Inc. (GRCE)

Reporting relationship: Director
Issuer ticker: GRCE
Reported as of: 17 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Sep 2026, 16:15:03 UTC
Prior SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert DelAversano as attorney-in-fact for Vimal Kavuru

Key filing fact

Vimal Kavuru filed Form 4 for Grace Therapeutics, Inc. (GRCE) on 21 Sep 2026.

Key facts

This page summarizes Vimal Kavuru's Form 4 filing for Grace Therapeutics, Inc. (GRCE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Sep 2026, 16:15.

Change

Previous filing in this sequence was filed on 12 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001697184 Primary reporting owner

Kavuru Vimal

Relationship: Director
Address: C/O GRACE THERAPEUTICS, INC., 103 CARNEGIE CENTER, SUITE 300, PRINCETON
Signature: /s/ Robert DelAversano as attorney-in-fact for Vimal Kavuru
Signature date: 21 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRCE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +12,200
Change %
Price: $0.000000^*
Shares after: 12,200
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,200
Exercise price: $2.13
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.